Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Wednesday, Dawson James Securities reiterated its Market Outperform rating and $4.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX).Dawson James Securities noted, “We maintain our Market Outperform rating and $4 price target on KERX shares. We derive our $4 price target by the synthesis of our DCF valuation ($3.73), comparables analysis (~$5.00), and our standardized CAGR methodology ($5.77). Risks to our valuation included clinical and regulatory, partnering, competitive, reimbursement, intellectual property and financial.”Keryx Biopharmaceuticals closed on Tuesday at $2.93.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!